Fri, Oct 24, 2014, 5:33 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Geron Corporation (GERN) Message Board

pedmac2000 69 posts  |  Last Activity: 7 hours ago Member since: Jul 15, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    GREAT NEWS

    by moneyme123 8 hours ago
    pedmac2000 pedmac2000 7 hours ago Flag

    funny no comments on board today

  • pedmac2000 pedmac2000 Oct 21, 2014 8:41 AM Flag

    i have written them as well.. i usually get a reply ..but nothing from my email yesterday.. .. keep up the fight.

  • pedmac2000 pedmac2000 Oct 20, 2014 10:04 AM Flag

    they don't give us any updates...... all up to us.. its ridiculous... only good thing is we have a chance to accumulate at these levels..

  • Reply to

    $2.00 call options

    by beavertail_splash Oct 17, 2014 1:13 PM
    pedmac2000 pedmac2000 Oct 17, 2014 6:09 PM Flag

    congrats ..

  • Reply to

    $2.00 call options

    by beavertail_splash Oct 17, 2014 1:13 PM
    pedmac2000 pedmac2000 Oct 17, 2014 2:43 PM Flag

    good luck .. i have seen the mm mess with options alot and it scares me to be honest... we need the hold to be lifted.. asap

  • pedmac2000 pedmac2000 Oct 17, 2014 9:15 AM Flag

    Maybe the ceo of Vical .. Vj?

  • Reply to

    QS21 in 16 undisclosed programs

    by atlantic95 Oct 16, 2014 8:21 AM
    pedmac2000 pedmac2000 Oct 16, 2014 8:51 AM Flag

    Good question...... i have been trying to search and search but it seems to be top secret............. i seem to remember they had .. some agreement for vaccine testing in bio terror...but obvioulsy not a word since.... anyway .. i just hope some company has something that works ..so we can get on with our lives and not worry about this horrible disease..

  • Reply to

    neuroblastomacanada

    by hayflicklim Oct 13, 2014 1:23 PM
    pedmac2000 pedmac2000 Oct 15, 2014 10:04 AM Flag

    what are you trying to say that we have competition? or proof that it works?

  • Reply to

    "The drug works"

    by sternjon Oct 8, 2014 9:45 AM
    pedmac2000 pedmac2000 Oct 8, 2014 9:57 AM Flag

    good reminder..
    im accumulating as much as i can .. i m about all out of nerve and cash... so hope the news is brilliant

  • Reply to

    health care worker dies for MARBURG

    by williambell369 Oct 6, 2014 5:06 PM
    pedmac2000 pedmac2000 Oct 8, 2014 9:33 AM Flag

    yeah .. nothing .. also nothing on the russian venture that was supposed to start years ago

  • Reply to

    magazine atrticle

    by priceray77 Oct 5, 2014 9:52 PM
    pedmac2000 pedmac2000 Oct 7, 2014 10:43 AM Flag

    I think BioDelivery Sciences International (BDSI) is also a terrific value, and I have made it one of my biggest holdings. The firm already has approval from the Food and Drug Administration for a drug with big potential. It has another drug that just produced excellent results in late-stage trials, and it has a third in early trials that could be a huge winner. The stock trades for just under $16 and boasts a market capitalization of $805 million.
    Advertisement

    BioDelivery Sciences has a lot going for it. In June, the FDA approved Bunavail, a treatment for dependence on opiates. The annual market for these kinds of drugs is $1.4 billion. “We expect peak sales of Bunavail will be 20% to 25% of the market,” says Al Medwar, a vice-president at Bio­Delivery. Based on the way investors value biotech stocks, if Bunavail generates annual sales of $300 million, that should be worth $900 million in stock market value, or 12% more than BioDelivery’s current market cap.

    In August, the company announced outstanding late-stage trial results for BEMA buprenorphine, its treatment for chronic pain. BioDelivery and its partner, Endo International (ENDP), plan to seek FDA approval for the drug late this year or early in 2015. When the application is filed, Endo will give BioDelivery $10 million, and it will hand over $50 million if the drug wins approval. Those would be significant chunks of change for such a small company. “There is a 90% chance of approval,” says analyst Jim Molloy, of Summer Street Research, an institutional research firm. “BEMA buprenorphine could be the next Vicodin.”

    Big potential. The drug in early trials is Clonidine, a topical gel for treating diabetic neuropathy pain. In August, BioDelivery doubled the number of participants in its Clonidine trial and said the analysis thus far was “very encouraging.” About 20% of the millions of diabetics in the U.S. suffer nerve-related pain. If Clonidine works, it could produce $300 million in annual sales. But millions of non-diabetics also suffer neuropathic pain, and current treatments are fairly ineffective. So annual Clonidine sales could conceivably hit $600 million.

    As a value investor, what I really like about BioDelivery Sciences is not so much that there are many ways to win as that there are almost no ways to lose. If initial sales of Bunavail prove disappointing, the stock could fall to $10. But it often takes time for a new drug to get traction, so that shouldn’t scare people out of the stock, especially given the high likelihood that BEMA buprenorphine will be approved and the reasonable chance that Clonidine will be as well. “With BDSI, you get tremendous downside protection,” says Molloy, whose one-year price target for the stock is $20. “My estimates are conservative. The stock could hit $40.”

    More on Promised Land »
    MORE FROM KIPLINGER

    Great Mutual Funds You Can Own for Just $100

    Editor#$%$ From Kiplinger

    10 Best Stocks for Socially Responsible Investors
    7 Great Growth Stocks with Long-Term Potential
    10 Worst ETFs for Your Portfolio

    You can get valuable updates like Promised Land from Kiplinger sent directly to your e-mail. Simply enter your e-mail address and click "sign up."
    Promoted Stories from Outbrain
    Recommended by
    One of the Biggest Retirement Mistakes
    One of the Biggest Retirement Mistakes
    (CNN Money)
    Choose the Right Time to Transfer Wealth to Your Heirs
    Choose the Right Time to Transfer Wealth to Your Heirs
    (Merrill Lynch)
    CNN Money: How Young Millionaires Invest
    CNN Money: How Young Millionaires Invest
    (CNN Money)
    7 Steps To Stock Investing Without Too Much Risk
    7 Steps To Stock Investing Without Too Much Risk
    (Forbes)
    One of the Biggest Retirement Mistakes
    Choose the Right Time to Transfer Wealth to Your Heirs
    CNN Money: How Young Millionaires Invest
    7 Steps To Stock Investing Without Too Much Risk

    MORE FROM KIPLINGER

    Best and Worst Buys at Trader Joe’s
    (kiplinger)
    How to Survive the Next Stock Market Correction
    (kiplinger)
    Calculating Required Distributions From Your Retirement Accounts
    (kiplinger)
    Best Things to Buy at Whole Foods
    (kiplinger)
    Where Do You Rank as a Taxpayer?
    (kiplinger)
    6 Tax Factors to Consider When Picking a Retirement Destination
    (kiplinger)

    More From Around the Web

    Living on Investment Income in Retirement, Part III: The Role of Risk in the Portfolio (Let's Make a Plan by CFP)
    How To Invest $100, $1,000, Or $10,000 (Business Insider)
    9 Things Around Your House That Need to Go in the Garbage ASAP (AARP)
    Little Known Way to Pay Off Mortgage (LendingTree)
    The 5 Best Credit Cards with No Interest to Help You Get out of Debt (NextAdvisor Daily)
    Young Investors Flock to Wealthfront, Eliminating Need for Typical Investment Managers (TechCrunch)

    Recommended by
    More Sponsored Links

    DISCUSS

    Permission to post your comment is assumed when you submit it. The name you provide will be used to identify your post, and NOT your e-mail address. We reserve the right to excerpt or edit any posted comments for clarity, appropriateness, civility, and relevance to the topic.
    View our full privacy policy

    Most Read
    Most Shared

    Worst Things to Buy at Trader Joe's - Slide Show
    9 Military Technologies That Will Change Warfare - Slide Show
    Worst Jobs for the Future - Slide Show
    10 Cheapest U.S. Cities to Live In - Slide Show
    What Not to Buy at Warehouse Clubs - Slide Show
    Worst Things to Buy on Amazon - Slide Show

    See More »
    Advertisement
    More Promised Land
    Other Columns

    Promising Bargains in Biotech Stocks
    Time-Tested Advice for Long-Term Investors
    Lessons From a Stock Pick That Gained 5,200%
    Two Surprising Telecom Stocks With Great Growth Potential
    Wall Street's Sleazy Reputation
    Andrew Feinberg’s 7 Stock Picks for 2014
    Conspiracy Theory Lessons for Investors

    See More »
    Market Update
    Advertisement

    DJIA 16,906-85.9
    S&P 500 1,957-7.4
    NASDAQ 4,440-14.6

    Rate Info

    Credit Cards
    Mortgage
    CD
    Auto
    Home Equity

    Rates quoted are national averages, recalculated weekly
    powered by
    Find rates:
    Featured Videos From Kiplinger

    Best Jobs for Your Future

    Kiplinger

    Best Deals on Used Cars

    Kiplinger

    Save Money on Car Repairs

    Kiplinger

    How to Get Free Samples

    Kiplinger

    Worst Jobs for Your Future

    Kiplinger

    Three Big Reasons You're Still Broke

    Kiplinger

    Best Jobs for Your Future

    Kiplinger

    Best Deals on Used Cars

    Kiplinger

    Money Poll
    How large of a nest egg do you think you will need to live comfortably in retirement?
    $500,000
    $1 million
    $1.5 million
    $2 million or more

    Read more at http://www.kiplinger.com/article/investing/T052-C018-S002-promising-bargains-in-biotech-stocks.html#lA8ZueUS11yS7dZR.99

  • Reply to

    magazine atrticle

    by priceray77 Oct 5, 2014 9:52 PM
    pedmac2000 pedmac2000 Oct 6, 2014 11:21 AM Flag

    thanks .. any more you can show us about this article?

  • AGENUS’ QS-21 STIMULON(R) ADJUVANT SELECTED FOR BIODEFENSE PROGRAM
    IMAGE AUGUST 13, 2014

    LEXINGTON, Mass., June 14, 2011 (GLOBE NEWSWIRE) — Agenus Inc. (Nasdaq:AGEN) announced today a license agreement with Integrated BioTherapeutics Inc.

  • Reply to

    Asterias & BioTime Warrant News

    by ebonymarangachachacha Sep 29, 2014 10:37 PM
    pedmac2000 pedmac2000 Sep 30, 2014 7:07 AM Flag

    now im confused.. what does this mean to us geron shareholders that got asty shares?

  • pedmac2000 pedmac2000 Sep 28, 2014 7:42 PM Flag

    rusty you are correct .. i have said same to Anna before as well..

  • pedmac2000 pedmac2000 Sep 28, 2014 5:34 PM Flag

    great article .. just google washington post shorts news

  • http://www.washingtonpost.com/business/northwest-biotherapeutics-stock-woes-highlight-the-harm-of-short-sales/2014/09/26/78b99b0a-4507-11e4-b47c-f5889e061e5f_story.html

  • http://www.washingtonpost.com/business/northwest-biotherapeutics-stock-woes-highlight-the-harm-of-short-sales/2014/09/26/78b99b0a-4507-11e4-b47c-f5889e061e5f_story.html

  • hope u can open it http://www.washingtonpost.com/business/northwest-biotherapeutics-stock-woes-highlight-the-harm-of-short-sales/2014/09/26/78b99b0a-4507-11e4-b47c-f5889e061e5f_story.html

  • pedmac2000 pedmac2000 Sep 26, 2014 10:29 AM Flag

    Per cc , think they are confident enough that they are going straight at FDA

GERN
2.23+0.02(+0.90%)Oct 24 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.